DBV Technologies is a late-stage specialty biopharmaceutical company focused on developing therapies for food allergies and other immunological conditions. The company utilizes its proprietary Viaskin technology platform, which delivers biologically active compounds to the immune system through intact skin via an epicutaneous patch. Its most advanced product candidate is the Viaskin Peanut Patch, intended for the treatment of peanut allergy in children, with a Biologics License Application planned for submission in the United States. The pipeline also includes the Viaskin Milk Patch for cow's milk allergy and cow's milk-induced eosinophilic esophagitis. DBV Technologies targets pediatric patients and caregivers in the United States and the European Union, engaging allergists, pediatricians, and payers for market access. The company was founded by pediatricians to address the unmet medical need of food allergies, aiming to provide a non-invasive immunotherapy option that minimizes systemic exposure.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage dbv-technologies.com
Sector Healthcare IR page dbv-technologies.com/investor-overview
Tags
epicutaneous immunotherapy, food allergy, peanut allergy, cow's milk allergy, eosinophilic esophagitis, pediatric immunology, skin patch delivery, biopharmaceuticals, Viaskin, Viaskin Peanut Patch, DBV712, Viaskin Milk Patch, DBV135
Press page —

Metrics

Valuation  
Market cap $ 3.697B
Market cap (USD) $ 3.697B
P/E -19.28
PEG —
P/BV 24.88
P/S 961.81
P/OCF -19.63
P/FCF -19.28
Dividend yield —
Turnover / mcap —
Returns  
ROE -149.8%
ROI -86.3%
ROIC -64.8%
Profit margin -2,607.3%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) —
Debt/Equity 0.13%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 38
Quality score -87.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 5.636M 0 0 0 0 0
Net profit -147.156M -114.123M -72.71M -96.008M -98.052M -159.665M
Free cash flow — — -78.321M -52.154M -104.968M -163.679M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 3.97 0.95 0.94 — — —
Price performance 12m 2.92 0 — — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 2.23M 0.00 0.00 0.00 0.00 —
↳ YoY growth -100.0%
Borrowings, current (USD) — 724,000 510,000 0.00 0.00 0.00 —
Borrowings, non-current (USD) — 543,000 0.00 0.00 0.00 0.00 —
Lease liabilities (USD) — 14.2M 10.2M 3.04M 5.67M 6.95M 6.53M
Cash and deposits (USD) 193M 196M 77.3M 209M 141M 32.5M 194M
Intangible assets (USD) — 41,000 22,000 10,000 57,000 40,000 22,000
Right-of-use assets (USD) — 9.88M 6.77M 2.46M 5.26M 5.39M 4.27M
Net debt (borrowings + leases - cash) (USD) — -181M -66.6M -206M -136M -25.5M —
Cash flow detail
Operating cash flow (USD) — -161M -104M -51.4M -77.6M -103M -120M
Purchases of property, plant and equipment (USD) — -2.79M -910,000 -754,000 -677,000 — —
Purchases of intangible assets (USD) — -29,000 -8,000 0.00 0.00 — —
Change in receivables (cash effect) (USD) — -2.07M 2.15M 0.00 0.00 0.00 —
Change in inventories (cash effect) (USD) — 2.33M 0.00 0.00 0.00 0.00 -16.1M
Change in payables (cash effect) (USD) — -5.08M -7.56M 3.46M 8.42M 296,000 15.5M
Share-based compensation (USD) — -1.13M 3.12M 5.03M 6.02M 4.62M 5.39M
Operating cash flow before change in receivables (USD) — -159M -106M -51.4M -77.6M -103M —
Free cash flow (OCF - PPE - intangibles) (USD) — -164M -105M -52.2M -78.3M — —
Income detail
Research and development expense (USD) — 101M 70.1M 75.2M 60.1M 89.2M 117M
↳ 5y CAGR +2.8%
Total comprehensive income (USD) — -136M -110M -104M -67M -118M -140M
Reported Mar 9, 2022 Mar 9, 2022 Mar 9, 2022 Mar 2, 2023 Mar 8, 2024 Apr 11, 2025 Mar 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Franchissement de seuils et déclaration d'intention Bull 0 Bear 0 Routine
Franchissement de seuils Bull 0 Bear 0 Routine

Prompts

DBV Technologies S.A. (ticker DBVT), listed in United States.

Company History

Date Change Detail
Sep 30, 2020 Reporting currency Its US reports are in USD instead of EUR from this period. Earlier figures are shown in USD, converted at each period end's exchange rate.

ETFs Holding DBV Technologies S.A.

ETF Weight in ETF Shares Market value As of
APIE 0.01% 4,402 $ 60.836K Aug 31, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
DBVT canonical Common share — US nasdaq 11.76 USD 2026-09-30
DBV Common share — FR euronext 3.02 EUR 2026-01-05